Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Balic Marija |

** = Publikationen gelistet in SCI/SSCI/Pubmed

2023

Originalarbeit (Zeitschrift)

** Beltran-Bless, AA; Clemons, MJ; Fesl, C; Greil, R; Pond, GR; Balic, M; Vandermeer, L; Bjelic-Radisic, V; Singer, CF; Steger, GG; Helfgott, R; Egle, D; Solkner, L; Gampenrieder, SP; Kacerovsky-Strobl, S; Suppan, C; Ritter, M; Rinnerthaler, G; Pfeiler, G; Fohler, H; Hlauschek, D; Hilton, J; Gnant, M Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
EUR J CANCER. 2023; 180: 108-116. Doi: 10.1016/j.ejca.2022.12.003
Web of Science PubMed FullText FullText_MUG

 

** Brcic, I; Kluba, AM; Godschachner, TM; Suppan, C; Regitnig, P; Dandachi, N; Lax, SF; Balić, M Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Int J Mol Sci. 2023; 24(1): Doi: 10.3390/ijms24010818 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gold, D; Nicolay, L; Avian, A; Greimel, E; Balic, M; Pristauz-Telsnigg, G; Tamussino, K; Trutnovsky, G Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: A randomized controlled trial.
Maturitas. 2023; 167: 1-7. Doi: 10.1016/j.maturitas.2022.08.013
PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Suppan, C; Balic, M Current standards and future outlooks in metastatic Her2-positive breast cancer
BREAST CARE. 2023; Doi: 10.1159/000528756
Web of Science FullText FullText_MUG

 

2022

Originalarbeit (Zeitschrift)

** Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083 Doi: 10.1002/cam4.4675 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Bartsch, R; Gampenrieder, SP; Rinnerthaler, G; Petru, E; Egle, D; Petzer, A; Balic, M; Pluschnig, U; Sliwa, T; Singer, C Updated Austrian treatment algorithm in HER2+metastatic breast cancer
WIEN KLIN WOCHENSCHR. 2022; 134(1-2): 63-72. Doi: 10.1007/s00508-021-01987-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stöger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Breast Care (Basel). 2022; 17(2):137-145 Doi: 10.1159/000516157 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Mayer, EL; Fesl, C; Hlauschek, D; Garcia-Estevez, L; Burstein, HJ; Zdenkowski, N; Wette, V; Miller, KD; Balic, M; Mayer, IA; Cameron, D; Winer, EP; Ponce, Lorenzo, JJ; Lake, D; Pristauz-Telsnigg, G; Haddad, TC; Shepherd, L; Iwata, H; Goetz, M; Cardoso, F; Traina, TA; Sabanathan, D; Breitenstein, U; Ackerl, K; Metzger, Filho, O; Zehetner, K; Solomon, K; El-Abed, S; Theall, KP; Lu, DR; Dueck, A; Gnant, M; DeMichele, A Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
J Clin Oncol. 2022; JCO2101918 Doi: 10.1200/JCO.21.01918 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Minichsdorfer, C; Fuereder, T; Leutner, M; Singer, CF; Kacerovsky-Strobl, S; Egle, D; Greil, R; Balic, M; Fitzal, F; Pfeiler, G; Frantal, S; Bartsch, R; Gnant, M Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.
ESMO Open. 2022; 7(2):100426 Doi: 10.1016/j.esmoop.2022.100426 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Posch, F; Niedrist, T; Glantschnig, T; Firla, S; Moik, F; Kolesnik, E; Wallner, M; Verheyen, N; Jost, PJ; Zirlik, A; Pichler, M; Balic, M; Rainer, PP Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer.
Front Cardiovasc Med. 2022; 9: 933428 Doi: 10.3389/fcvm.2022.933428 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Singer, C; Petru, E; Egle, D; Petzer, A; Pluschnig, U; Gampenrieder, SP; Pfeiler, G; Gnant, M; Grunberger, B; Krippl, P; Strasser-Weippl, K; Suppan, C; Brunner, C; Pusch, R; Sandholzer, M; Balic, M; Bartsch, R Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
WIEN KLIN WOCHENSCHR. 2022; Doi: 10.1007/s00508-022-02082-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Suppan, C; Graf, R; Jahn, S; Zhou, Q; Klocker, EV; Bartsch, R; Terbuch, A; Kashofer, K; Regitnig, P; Lindenmann, J; Posch, F; Gerritsmann, H; Jost, PJ; Heitzer, E; Dandachi, N; Balic, M Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer. 2022; 126(3):456-463 Doi: 10.1038/s41416-021-01601-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Westphal, T; Gampenrieder, SP; Rinnerthaler, G; Balic, M; Posch, F; Dandachi, N; Hauser-Kronberger, C; Reitsamer, R; Sotlar, K; Radl, B; Suppan, C; Stöger, H; Greil, R Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT).
Breast Care (Basel). 2022; 17(1): 1-9. Doi: 10.1159/000512467 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Clin Cancer Res. 2022; 28(4):697-707 Doi: 10.1158/1078-0432.CCR-21-3231 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Hauser, H; Hammer, R; Schollnast, H; Humer-Fuchs, U; Kriegl, D; Fuchsjager, M; Schmidt, F; Balic, M; Lax, SF Malignant phyllodes tumor of the breast with axillary lymph node metastasis: case report and review of the literature
EUR SURG. 2022; Doi: 10.1007/s10353-022-00760-0 (- Case Report)
Web of Science FullText FullText_MUG

 

** Klocker, EV; Balic, M; Steger, G Molecular profiling leading to personalized treatment in breast cancer
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-021-00792-4
Web of Science FullText FullText_MUG

 

Editorial

** Bartsch, R; Balic, M EVOLUTION OF HER2-TARGETING IN METASTATIC BREAST CANCER
BREAST CARE. 2022; Doi: 10.1159/000528002
Web of Science FullText FullText_MUG

 

** Dandachi, N; Balic, M Deciphering the molecular landscape of metastatic lobular breast cancer
EBIOMEDICINE. 2022; 86: 104385 Doi: 10.1016/j.ebiom.2022.104385 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rezension

** Balic, M; Wimmer, K; Suppan, C; Silovski, T; Brunner, C Expert Discussion: ASCO 2022
BREAST CARE. 2022; 17(4): 430-436. Doi: 10.1159/000525966 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Zeitschrift)

** Balic, M; Posch, F; Bartsch, R Phase II Study of Neratinib and Trastuzumab plus -oral Vinorelbine in previously treated metastatic Her2 positive Breast Cancer
ONCOL RES TREAT. 2022; 45(SUPPL 2): 106-106. [Poster]
Web of Science

 

** Harbeck, N; Wrobel, D; Zaiss, M; Guth, D; Distelrath, A; Terhaag, J; Lorenz, A; Bartsch, R; Breitenstein, U; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Luftner, D Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ANN ONCOL. 2022; 33: S157-S157. Doi: 10.1016/j.annonc.2022.03.091 [Poster]
Web of Science FullText FullText_MUG

 

** Luftner, D; Bartsch, R; Breitenstein, U; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Schwitter, M; Zaman, K; Wrobel, D; Guth, D; Terhaag, J; Zaiss, M; Distelrath, A; Lorenz, A; Schinkothe, T; Harbeck, N Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ONCOL RES TREAT. 2022; 45(SUPPL 3): 20-21. [Poster]
Web of Science

 

** Marme, F; Hanusch, C; Furlanetto, J; Morris, P; Link, T; Denkert, C; Fasching, PA; Jackisch, C; Antolin, S; Solbach, C; Aftimos, P; Huober, J; Untch, M; Balic, M; Reinisch, M; Blohmer, JU; Concalves, A; Rey, J; Buchele, T; Loibl, S Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT)
ONCOL RES TREAT. 2022; 45(SUPPL 3): 30-30. [Poster]
Web of Science

 

** Marme, F; Hanusch, C; Furlanetto, J; Morris, P; Link, T; Denkert, C; Fasching, PA; Jackisch, C; Antolin, S; Solbach, C; Aftimos, P; Huober, J; Untch, M; Balic, M; Reinisch, M; Blohmer, JU; Goncalves, A; Rey, J; Buchele, T; Loibl, S Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
ANN ONCOL. 2022; 33: S148-S149. Doi: 10.1016/j.annonc.2022.03.074 [Poster]
Web of Science FullText FullText_MUG

 

** Pfeiler, G; Hlauschek, D; Mayer, EL; Deutschmann, C; Kacerovsky-Strobl, S; Martin, M; Meisel, JL; Zdenkowski, N; Loibl, S; Balic, M; Park, H; Prat, A; Isaacs, C; Machacek-Link, J; Schurmans, C; Theall, KP; Fesl, C; Dueck, AC; DeMichele, A; Gnant, M Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
J CLIN ONCOL. 2022; 40(16): [Poster]
Web of Science

 

** Singer, CF; Egle, D; Greil, R; Petru, E; Ohler, L; Balic, M; Tinchon, C; Pfeiler, G; Marhold, M; Brunner, C; Haider, K; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Uthman, S; Mraz, B; Bartsch, R REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis
ANN ONCOL. 2022; 33: S217-S217. Doi: 10.1016/j.annonc.2022.03.214 [Poster]
Web of Science FullText FullText_MUG

 

2021

Originalarbeit (Zeitschrift)

** Bartsch, R; Singer, CF; Pfeiler, G; Hubalek, M; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Muy-Kheng, TM; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Br J Cancer. 2021; 124(11): 1795-1802. Doi: 10.1038/s41416-021-01284-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Dandachi, N; Posch, F; Graf, R; Suppan, C; Klocker, EV; Müller, HD; Lindenmann, J; Terbuch, A; Heitzer, E; Balic, M Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment.
Mol Oncol. 2021; 15(9):2390-2400 Doi: 10.1002/1878-0261.12870 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Filipits, M; Rudas, M; Kainz, V; Singer, CF; Fitzal, F; Bago-Horvath, Z; Greil, R; Balic, M; Regitnig, P; Halper, S; Hulla, W; Egle, D; Barron, S; Loughman, T; O'Leary, D; Gallagher, WM; Hlauschek, D; Gnant, M; Dubsky, P The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Clin Cancer Res. 2021; 27(21):5931-5938 Doi: 10.1158/1078-0432.CCR-21-1023
Web of Science PubMed FullText FullText_MUG

 

** Filipits, M; Rudas, M; Singer, CF; Fitzal, F; Bago-Horvath, Z; Greil, R; Balic, M; Lax, SF; Halper, S; Hulla, W; Wu, NC; Liu, X; Weidler, J; Bates, M; Hlauschek, D; Gnant, M; Dubsky, P ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
ESMO Open. 2021; 6(4): 100228 Doi: 10.1016/j.esmoop.2021.100228 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Fitzal, F; Filipits, M; Fesl, C; Rudas, M; Greil, R; Balic, M; Moinfar, F; Herz, W; Dubsky, P; Bartsch, R; Ferree, S; Schaper, C; Gnant, M; Austrian Breast and Colorectal Cancer Study Group (ABCSG) PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Br J Surg. 2021; 108(3): 308-314. Doi: 10.1093/bjs/znaa089 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Gampenrieder, SP; Pircher, M; Fesl, C; Rinnerthaler, G; Mlineritsch, B; Greil-Ressler, S; Steger, GG; Sagaster, V; Fitzal, F; Exner, R; Devyatko, Y; Balic, M; Stoger, H; Suppan, C; Bauernhofer, T; Singer, CF; Pfeiler, G; Seifert, M; Helfgott, R; Heck, D; Rumpold, H; Kwasny, W; Wieder, U; Gnant, M; Greil, R Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
BREAST CARE. 2021; Doi: 10.1159/000516157
Web of Science FullText FullText_MUG

 

** Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, A; Balic, M; Heibl, S; Schmitt, C; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Hager, C; Andel, J; Hubalek, M; Knauer, M; Greil, R Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
BREAST CANCER RES. 2021; 23(1): 112 Doi: 10.1186/s13058-021-01492-x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gnant, M; Fitzal, F; Rinnerthaler, G; Steger, GG; Greil-Ressler, S; Balic, M; Heck, D; Jakesz, R; Thaler, J; Egle, D; Manfreda, D; Bjelic-Radisic, V; Wieder, U; Singer, CF; Melbinger-Zeinitzer, E; Haslbauer, F; Sevelda, P; Trapl, H; Wette, V; Wimmer, K; Gampenrieder, SP; Bartsch, R; Kacerovsky-Strobl, S; Suppan, C; Brunner, C; Deutschmann, C; Soelkner, L; Fesl, C; Greil, R, , Austrian, Breast, and, Colorectal, Cancer, Study, Group;Austrian, Breast, and, Colorectal, Cancer, Study, Group Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
N Engl J Med. 2021; 385(5):395-405 Doi: 10.1056/NEJMoa2104162
Web of Science PubMed FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Hubalek, M; Petru, E; Sandholzer, M; Andel, J; Balic, M; Melchardt, T; Hauser-Kronberger, C; Schmitt, CA; Ulmer, H; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6).
Ther Adv Med Oncol. 2021; 13: 17588359211042301 Doi: 10.1177/17588359211042301 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Müller, V; Balic, M; Zaman, K; Dieci, MV Expert Discussion: Immunotherapy in Breast Cancer - Ready for Prime Time?
Breast Care (Basel). 2021; 16(2): 188-191. Doi: 10.1159/000515746 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Suppan, C; Posch, F; Mueller, HD; Mischitz, N; Steiner, D; Klocker, EV; Setaffy, L; Bargfrieder, U; Hammer, R; Hauser, H; Jost, PJ; Dandachi, N; Lax, S; Balic, M Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.
Cancers (Basel). 2021; 13(10): Doi: 10.3390/cancers13102492 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Suppan, C; Steiner, D; Klocker, EV; Posch, F; Henzinger, E; Muller, HD; Stoger, H; Dandachi, N; Balic, M Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
BREAST CARE. 2021; Doi: 10.1159/000513766 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Westphal, T; Gampenrieder, SP; Rinnerthaler, G; Balic, M; Posch, F; Dandachi, N; Hauser-Kronberger, C; Reitsamer, R; Sotlar, K; Radl, B; Suppan, C; Stoger, H; Greil, R Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT)
BREAST CARE. 2021; Doi: 10.1159/000512467
Web of Science FullText FullText_MUG

 

Übersichtsarbeit

** Balic, M; Rinnerthaler, G; Bartsch, R Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer
BREAST CARE. 2021; Doi: 10.1159/000518696 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Thomssen, C; Balic, M; Harbeck, N; Gnant, M St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer.
BREAST CARE. 2021; 16(2): 135-143. Doi: 10.1159/000516114 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Editorial

** Balic, M Best of SABCS 2020
MEMO-MAG EUR MED ONC. 2021; 14(3): 216-217. Doi: 10.1007/s12254-021-00744-y
Web of Science FullText FullText_MUG

 

Abstract (Zeitschrift)

** Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, AL; Balic, M; Heibl, S; Zabernigg, A; Egle, D; Sandholzer, M; Roitner, F; Andel, J; Pichler, P; Hager, C; Hubalek, M; Knauer, M; Singer, CF; Greil, R Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
ANN ONCOL. 2021; 32: S487-S488. Doi: 10.1016/j.annonc.2021.08.566 [Poster]
Web of Science FullText FullText_MUG

 

** Nicolay, L; Avian, A; Pristauz-Telsnigg, G; Balic, M; Tamussino, K; Trutnovsky, G; Gold, D Vaginal Laser Therapy versus Hyaluronic Acid Suppositories in Women with genitourinary Menopausal Syndrome after Breast Cancer Treatment: A randomized controlled Trial
GEBURTSH FRAUENHEILK. Kongressabstracts. 2021; 81(06):E27-E27.-Gemeinsamen Jahrestagung der OEGGG und der BGGF; JUN 2-5, 2021; Virtuell, DEUTSCHLAND. Doi: 10.1055/s-0041-1730508 [Onlinepräsentation]
Web of Science FullText FullText_MUG

 

** Suppan, C; Zhou, Q; Jahn, S; Graf, R; Klocker, EV; Terbuch, A; Kashofer, K; Posch, F; Gerritsmann, H; Dandachi, N; Heitzer, E; Balic, M Comparison of liquid biopsy and tissue based detection of PIK3CAmutations in HR positive metastatic breast cancer patients
CANCER RES. 2021; 81(4): [Poster]
Web of Science

 

Kommentar

** Aftimos, P; Oliveira, M; Irrthum, A; Fumagalli, D; Sotiriou, C; Gal-Yam, EN; Robson, ME; Ndozeng, J; Di, Leo, A; Ciruelos, EM; de, Azambuja, E; Viale, G; Scheepers, ED; Curigliano, G; Bliss, JM; Reis-Filho, JS; Colleoni, M; Balic, M; Cardoso, F; Albanell, J; Duhem, C; Marreaud, S; Romagnoli, D; Rojas, B; Gombos, A; Wildiers, H; Guerrero-Zotano, A; Hall, P; Bonetti, A; Larsson, KF; Degiorgis, M; Khodaverdi, S; Greil, R; Sverrisdóttir, Á; Paoli, M; Seyll, E; Loibl, S; Linderholm, B; Zoppoli, G; Davidson, NE; Johannsson, OT; Bedard, PL; Loi, S; Knox, S; Cameron, DA; Harbeck, N; Montoya, ML; Brandão, M; Vingiani, A; Caballero, C; Hilbers, FS; Yates, LR; Benelli, M; Venet, D; Piccart, MJ Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Cancer Discov. 2021; 11(11): 2796-2811. Doi: 10.1158/2159-8290.CD-20-1647 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2020

Originalarbeit (Zeitschrift)

** Bjelic-Radisic, V; Fitzal, F; Knauer, M; Steger, G; Egle, D; Greil, R; Schrenk, P; Balic, M; Singer, C; Exner, R; Soelkner, L; Gnant, M; ABCSG Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.
BMC Cancer. 2020; 20(1): 392-392. Doi: 10.1186/s12885-020-06894-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Dubsky, PC; Singer, CF; Egle, D; Wette, V; Petru, E; Balic, M; Pichler, A; Greil, R; Petzer, AL; Bago-Horvath, Z; Fesl, C; Meek, SM; Kronenwett, R; Rudas, M; Gnant, M; Filipits, M; Austrian Breast and Colorectal Cancer Study Group The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Eur J Cancer. 2020; 134:99-106 Doi: 10.1016/j.ejca.2020.04.020 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Fesl, C; Sölkner, L; Greil, R; Jakesz, R; Kwasny, W; Heck, D; Bjelic-Radisic, V; Balic, M; Stöger, H; Wieder, U; Zwrtek, R; Semmler, D; Horvath, W; Melbinger-Zeinitzer, E; Wiesholzer, M; Wette, V; Gnant, M Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.
Eur J Cancer. 2020; 127(4):12-20 Doi: 10.1016/j.ejca.2019.11.024
Web of Science PubMed FullText FullText_MUG

 

** Jahn, SW; Bösl, A; Tsybrovskyy, O; Gruber-Rossipal, C; Helfgott, R; Fitzal, F; Knauer, M; Balic, M; Jasarevic, Z; Offner, F; Moinfar, F Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
Br J Cancer. 2020; 122(12):1744-1746 Doi: 10.1038/s41416-020-0838-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Lindenmann, J; Fediuk, M; Fink-Neuboeck, N; Porubsky, C; Pichler, M; Brcic, L; Anegg, U; Balic, M; Dandachi, N; Maier, A; Smolle, M; Smolle, J; Smolle-Juettner, FM Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer.
Cancers (Basel). 2020; 12(8): Doi: 10.3390/cancers12082066 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Lindenmann, J; Fink-Neuboeck, N; Fediuk, M; Maier, A; Kovacs, G; Balic, M; Smolle, J; Smolle-Juettner, FM Preoperative Peak Oxygen Consumption: A Predictor of Survival in Resected Lung Cancer.
Cancers (Basel). 2020; 12(4): Doi: 10.3390/cancers12040836 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Perakis, SO; Weber, S; Zhou, Q; Graf, R; Hojas, S; Riedl, JM; Gerger, A; Dandachi, N; Balic, M; Hoefler, G; Schuuring, E; Groen, HJM; Geigl, JB; Heitzer, E; Speicher, MR Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer.
ESMO Open. 2020; 5(5):e000872 Doi: 10.1136/esmoopen-2020-000872 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8): Doi: 10.3390/cancers12082319 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Sestak, I; Filipits, M; Buus, R; Rudas, M; Balic, M; Knauer, M; Kronenwett, R; Fitzal, F; Cuzick, J; Gnant, M; Greil, R; Dowsett, M; Dubsky, P Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
Clin Cancer Res. 2020; 26(17): 4682-4687. Doi: 10.1158/1078-0432.CCR-20-0260
Web of Science PubMed FullText FullText_MUG

 

** Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stöger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Maria Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M; Austrian Breast & Colorectal Cancer Study Group Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
Eur J Cancer. 2020; 132:43-52 Doi: 10.1016/j.ejca.2020.03.018
Web of Science PubMed FullText FullText_MUG

 

Kurzbericht/Letter

** Suppan, C; Balic, M Treatment options in early triple-negative breast cancer Update from the San Antonio Breast Cancer Symposium 2019.
MEMO-MAG EUR MED ONC. 2020; Doi: 10.1007/s12254-020-00609-w [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Editorial

** Balic, M Understanding and Treating HER Better.
Breast Care (Basel). 2020; 15(6):557-559 Doi: 10.1159/000512415 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Suppan, C; Balic, M It is time to prepare for D-CARE!
ANN TRANSL MED. 2020; 8(21): 1339 Doi: 10.21037/atm-2020-99 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Zeitschrift)

** Gampenrieder, SP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R Landscape of HER2-low metastatic breast cancer (MBC): Results from the AGMT-MBC-Registry.
CANCER RES. 2020; 80(4):-San Antonio Breast Cancer Symposium; DEC 10-14, 2019; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS19-P3-08-29 [Poster]
Web of Science FullText FullText_MUG

 

** Perakis, SO; Weber, S; Graf, R; Zhou, Q; Riedl, JM; Dandachi, N; Balic, M; Gerger, A; Schuuring, E; Groen, HJ; Geigl, JB; Speicher, MR; Heitzer, E Identification of actionable targets in advanced cancer patients from circulating tumor DNA using clinical decision support platforms
CANCER RES. 2020; 80(16):-AACR Annual Meeting; JUN 22-24, 2020; ELECTR NETWORK. Doi: 10.1158/1538-7445.AM2020-1315 [Poster]
Web of Science FullText FullText_MUG

 

** Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.234 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R Prognosis of triple negative metastatic breast cancer (MBC): Results from the AGMT_MBC-Registry.
CANCER RES. 2020; 80(4):-San Antonio Breast Cancer Symposium; DEC 10-14, 2019; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS19-P5-06-29 [Poster]
Web of Science FullText FullText_MUG

 

** Suppan, C; Steiner, D; Klocker, VE; Posch, F; Henzinger, EC; Stoeger, H; Dandachi, N; Balic, M Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.
J CLIN ONCOL. 2020; 38(15): [Onlinepräsentation]
Web of Science FullText

 

** Suppan, C; Zhou, Q; Graf, R; Klocker, V; Terbuch, A; Dandachi, N; Heitzer, E; Balic, M Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastastic breast cancer patients.
ANN ONCOL. 2020; 31: S41-S41.-ESMO Breast Cancer Virtual Meeting; MAY 23-24, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.03.213 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Diskussion

** Witzel, I; Lambertini, M; Balic, M; Wuerstlein, R; Müller, V Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019.
Breast Care (Basel). 2020; 15(2): 192-196. Doi: 10.1159/000506098 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kommentar

** Bago-Horvath, Z; Rudas, M; Singer, CF; Greil, R; Balic, M; Lax, SF; Kwasny, W; Hulla, W; Gnant, M; Filipits, M Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Clin Cancer Res. 2020; 26(21): 5682-5688. Doi: 10.1158/1078-0432.CCR-20-0673
Web of Science PubMed FullText FullText_MUG

 

2019

Originalarbeit (Zeitschrift)

** Balic, M; Hilbe, W; Gusel, S; Fiegl, M; Ludwig, H; Mayrbaurl, B; Thaler, J; Samonigg, H; Hegenbarth, K; Eisner, F; Mlineritsch, B; Greil, R; Schandl, MJ; Weltermann, A; Petzer, A; Fuchs, D; Stangl, W; Krippl, P; Stauder, R; Stoger, H Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria A cross-sectional multicentre observational study
MEMO-MAG EUR MED ONC. 2019; Doi: 10.1007/s12254-019-00542-7 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, CF; Hlauschek, D; Brown, K; Bernhisel, R; Kronenwett, R; Lancaster, JM; Fitzal, F; Gnant, M Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.
Clin Cancer Res. 2019; 25(13):3865-3872 Doi: 10.1158/1078-0432.CCR-19-0376 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Fitzal, F; Bjelic-Radisic, V; Knauer, M; Steger, G; Hubalek, M; Balic, M; Singer, C; Bartsch, R; Schrenk, P; Soelkner, L; Greil, R; Gnant, M Impact of Breast Surgery in Primary Metastasized Breast Cancer Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial
ANN SURG. 2019; 269(6): 1163-1169. Doi: 10.1097/SLA.0000000000002771
Web of Science PubMed FullText FullText_MUG

 

** Gnant, M; Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF, , Austrian, Breast, and, Colorectal, Cancer, Study, Group Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol. 2019; 20(3):339-351 Doi: 10.1016/S1470-2045(18)30862-3
Web of Science PubMed FullText FullText_MUG

 

** Čipak Gašparović, A; Milković, L; Dandachi, N; Stanzer, S; Pezdirc, I; Vrančić, J; Šitić, S; Suppan, C; Balic, M Chronic Oxidative Stress Promotes Molecular Changes Associated with Epithelial Mesenchymal Transition, NRF2, and Breast Cancer Stem Cell Phenotype.
Antioxidants (Basel). 2019; 8(12): 633 Doi: 10.3390/antiox8120633 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Müller, HD; Posch, F; Suppan, C; Bargfrieder, U; Gumpoldsberger, M; Hammer, R; Hauser, H; Dandachi, N; Prein, K; Stoeger, H; Lax, S; Balic, M Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
Ann Surg Oncol. 2019; 26(13):4274-4283 Doi: 10.1245/s10434-019-07741-w [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Suppan, C; Brcic, I; Tiran, V; Mueller, HD; Posch, F; Auer, M; Ercan, E; Ulz, P; Cote, RJ; Datar, RH; Dandachi, N; Heitzer, E; Balic, M Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.
Cancers (Basel). 2019; 11(8): Doi: 10.3390/cancers11081171 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Vehabovic-Delic, A; Balic, M; Rossmann, C; Bauernhofer, T; Deutschmann, HA; Schoellnast, H Volume Computed Tomography Perfusion Imaging: Evaluation of the Significance in Oncologic Follow-up of Metastasizing Renal Cell Carcinoma in the Early Period of Targeted Therapy - Preliminary Results.
J Comput Assist Tomogr. 2019; 43(3):493-498 Doi: 10.1097/RCT.0000000000000848
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Balic, M; Thomssen, C; Würstlein, R; Gnant, M; Harbeck, N St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment.
Breast Care (Basel). 2019; 14(2):103-110 Doi: 10.1159/000499931 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Suppan, C; Balic, M Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer The best of ASCO 2019
MEMO-MAG EUR MED ONC. 2019; Doi: 10.1007/s12254-019-00530-x [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Abstract (Zeitschrift)

** Balic, M; Suppan, C; Brcic, I; Tiran, V; Mueller, DH; Posch, F; Ulz, P; Heitzer, E; Dandachi, N Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
ANN ONCOL. 2019; 30: 110-+.-44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN. [Poster]
Web of Science

 

** Dandachi, N; Absenger, G; Brcic, L; Kashofer, K; Terbuch, A; Jaritz, L; Stanzer, S; Balic, M Feasibility and clinical value of serial circulating tumor DNA testing in metastatic lung adenocarcinoma patients undergoing TKI treatment
ONCOL RES TREAT. 2019; 42: 213-213. [Poster]
Web of Science

 

** Dandachi, N; Suppan, C; Brcic, L; Tiran, V; Mueller, DH; Posch, F; Ulz, P; Heitzer, E; Balic, M Monitoring therapy response and assessing prognosis by untargeted FAST-SeqS of circulating tumor DNA in metastatic breast cancer patients
ONCOL RES TREAT. 2019; 42: 41-41. [Poster]
Web of Science

 

** Devyatko, Y; Filipits, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, C; Fitzal, F; Steger, G; Gray, B; Ferree, S; Fesl, C; Soelkner, L; von Minckwitz, G; Gnant, M The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer
CANCER RES. 2019; 79(4): Doi: 10.1158/1538-7445.SABCS18-P1-17-05 [Poster]
Web of Science FullText FullText_MUG

 

** Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Kwasny, W; Heck, D; Bjelic-Radisic, V; Balic, M; Stoger, H; Wieder, U; Zwrtek, R; Semmler, D; Horvath, W; Melbinger-Zeinitzer, E; Wiesholzer, M; Wette, V; Gnant, M Antihormones with or without irradiation in breast cancer: 10-year results of the ABCSG 8A trial
RADIOTHER ONCOL. 2019; 133: S132-S133.-38th Annual Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO); APR 26-30, 2019; Milan, ITALY. Doi: 10.1016/S0167-8140(19)30690-5 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Fediuk, M; Fink-Neubock, N; Maier, A; Lindenmann, J; Balic, M; Smolle-Juttner, FM Bronchial Cancer - personalized
WIEN KLIN WOCHENSCHR. 2019; 131(19-20):508-508. [Oral Communication]
Web of Science

 

** Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Fitzal, F; Bago-Horvath, Z; Singer, C; Hlauschek, D; Kronenwett, R; Bernhisel, R; Lancaster, J; Gnant, M Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years
CANCER RES. 2019; 79(4):-San Antonio Breast Cancer Symposium; DEC 04-08, 2018; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS18-P4-08-05 [Poster]
Web of Science FullText FullText_MUG

 

** Gampenrieder, SPP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry
ANN ONCOL. 2019; 30: 126-+.-44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN. [Poster]
Web of Science

 

** Posch, F; Glantschnig, T; Firla, S; Smolle, M; Balic, M; Moik, F; Stoeger, H; Zirlik, A; Pichler, M; Rainer, P Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+early breast cancer undergoing trastuzumab-based therapy
EUR HEART J. 2019; 40: 3844-3844.-ESC Congress / World Congress of Cardiology; AUG 31-SEP 04, 2019; Paris, FRANCE. [Poster]
Web of Science

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
CANCER RES. 2019; 79(4):-San Antonio Breast Cancer Symposium; DEC 04-08, 2018; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS18-OT3-07-01 [Poster]
Web of Science FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R First data on overall survival of metastatic breast cancer patients in Austria according to breast cancer subtype: results from the AGMT MBC Registry
ONCOL RES TREAT. 2019; 42: 40-40.
Web of Science

 

** Singer, CF; Oehler, L; Egle, D; Greil, R; Petru, E; Balic, M; Marhold, M; Pfeiler, G; Brunner, C; Kwasny, W; Galid, AA; Tinchon, C; Eisterer, W; Haslbauer, F; Hubalek, M; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Steger, GG REACHAUT: First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) in the real-world setting.
J CLIN ONCOL. 2019; 37(15):-Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO); MAY 31-JUN 04, 2019; Chicago, IL. Doi: 10.1200/JCO.2019.37.15_suppl.e12527 [Poster]
Web of Science FullText FullText_MUG

 

2018

Originalarbeit (Zeitschrift)

** Agarwal, A; Balic, M; El-Ashry, D; Cote, RJ Circulating Tumor Cells: Strategies for Capture, Analyses, and Propagation.
Cancer J. 2018; 24(2):70-77 Doi: 10.1097/PPO.0000000000000310 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Brcic, L; Stanzer, S; Krenbek, D; Gruber-Moesenbacher, U; Absenger, G; Quehenberger, F; Valipour, A; Lindenmann, J; Stoeger, H; Al Effah, M; Fediuk, M; Balic, M; Popper, HH Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.
Virchows Arch. 2018; 472(4):589-598 Doi: 10.1007/s00428-018-2326-0 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Fuchs, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Bartsch, R; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
BMC CANCER. 2018; 18(1): 1074-1074. Doi: 10.1186/s12885-018-4979-0 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Editorial

** Balic, M Still making progress
MEMO-MAG EUR MED ONC. 2018; 11(3): 166-167. Doi: 10.1007/s12254-018-0434-9 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Abstract (Zeitschrift)

** Balic, M; Mueller, DH; Hammer, R; Gumpoldsberger, M; Suppan, C; Posch, F; Stoeger, H; Dandachi, N; Prein, K; Hauser, H; Lax, S Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Poster]
Web of Science

 

** Dubsky, PC; Fesl, C; Singer, CF; Pfeiler, G; Kronenwett, R; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzner, AL; Sevelda, P; Egle, D; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Lax, S; Regitnig, P; Gnant, M; Filipits, M The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Oral Communication]
Web of Science

 

** Filipits, M; Rudas, M; Singer, C; Bago-Horvath, Z; Greil, R; Balic, M; Lax, SF; Wu, N; Zhao, S; Weidler, J; Bates, M; Hlauschek, D; Gnant, M; Dubsky, P mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort
ANN ONCOL. 2018; 29: 480-480.-43rd ESMO Congress (ESMO); OCT 19-23, 2018; Munich, GERMANY. [Poster]
Web of Science

 

** Gasparovic, AC; Milkovic, L; Sitic, S; Pezdirc, I; Vrancic, J; Stanzer, S; Dandachi, N; Balic, M Role of 4-hydroxynonenal in communication between cancer stem cells and microenvironment
FREE RADICAL BIO MED. . 2018; 124: 563-563.-International HNE-Club Meeting; SEP, 2017; Graz, AUSTRIA. Doi: 10.1016/j.freeradbiomed.2018.05.025 [Oral Communication]
Web of Science FullText FullText_MUG

 

** Gnant, M; Steger, G; Greil, R; Fitzal, F; Mlineritsch, B; Manfreda, D; Tausch, C; Balic, M; Dubsky, P; Moik, M; Thaler, J; Egle, D; Bjelic-Radisic, V; Selim, U; Exner, R; Singer, C; Melbinger-Zeinitzer, E; Haslbauer, F; Stoger, H; Helfgott, R; Sevelda, P; Trapl, H; Wette, V; Solkner, L; Jakesz, R A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Oral Communication]
Web of Science

 

** Muller, HD; Posch, F; Gumpoldsberger, M; Suppan, C; Hammer, R; Hauser, H; Dandachi, N; Prein, K; Stoger, H; Lax, S; Balic, M Prognostic impact of the Residual Cancer Burden (RCB) index on recurrence-free survival of breast cancer patients recieving neoadjuvant therapy
ONCOL RES TREAT. 2018; 41: 297-298. [Poster]
Web of Science

 

** Pereyra, D; Bee, A; Duerr, C; Lamm, C; Brostjan, C; Spittler, A; Starlinger, P; Steger, G; Balic, M; Gnant, M; Fitzal, F Pro-angiogenic profile after resection of primary tumour might be responsible for reduced outcome in patients with primary metastasized breast cancer
EUR J CANCER. 2018; 92: S137-S137.-11th European Breast Cancer Conference (EBCC); MAR 21-23, 2018; Barcelona, SPAIN. [Poster]
Web of Science

 

** Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Bergh, J; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF; Gnant, M Fracture Risk after Stopping Adjuvant Denosumab in Hormone Receptor Positive Breast Cancer Patients on Aromatase Inhibitor Therapy - an Analysis of 3,425 Postmenopausal Patients in the Phase III ABCSG-18 trial
J BONE MINER RES. 2018; 33: 55-55.-Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 28-OCT 01, 2018; Montreal, CANADA. [Keynote lecture]
Web of Science

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Fridrik, M; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, C; Bartsch, R; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial)
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX. [Poster]
Web of Science

 

** Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
CANCER RES. 2018; 78(13):-Annual Meeting of the American-Association-for-Cancer-Research (AACR); APR 14-18, 2018; Chicago, IL. Doi: 10.1158/1538-7445.AM2018-CT160 [Poster]
Web of Science FullText FullText_MUG

 

** Suppan, C; Brcic, I; Heitzer, E; Tiran, V; Mueller, HD; Auer, M; Cote, RJ; Datar, R; Dandachi, N; Balic, M Prognostic impact of tumor fractions in plasma assessed with mFAST-SeqS on overall survival of metastatic breast cancer undergoing systemic treatment
EUR J CANCER. 2018; 92: S136-S136.-11th European Breast Cancer Conference (EBCC); MAR 21-23, 2018; Barcelona, SPAIN. [Poster]
Web of Science

 

News-Item

** Balic, M; Dedic, N; De Mattos-Arruda, L; Gampenrieder, S News from ASCO 2018.
Breast Care (Basel). 2018; 13(4):298-302 Doi: 10.1159/000491564 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Originalarbeit (Zeitschrift)

** Balic, M; Bartsch, R; Bauernhofer, T; Vrbanec, D; Vrdoljak, E Biosimilars in the Treatment of Breast Cancer.
Breast Care (Basel). 2017; 12(3):192-194 Doi: 10.1159/000477926 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Benezeder, T; Tiran, V; Treitler, AAN; Suppan, C; Rossmann, C; Stoeger, H; Cote, RJ; Datar, RH; Balic, M; Dandachi, N Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients.
Oncotarget. 2017; 8(54):92483-92496 Doi: 10.18632/oncotarget.21426 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Dandachi, N; Tiran, V; Lindenmann, J; Brcic, L; Fink-Neuboeck, N; Kashofer, K; Absenger, G; Bezan, A; Cote, RJ; Datar, R; Balic, M Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas.
Lung Cancer. 2017; 113(46):152-157 Doi: 10.1016/j.lungcan.2017.10.003
Web of Science PubMed FullText FullText_MUG

 

** Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Moinfar, F; Gruber, C; Petru, E; Bartsch, R; Tendl, KA; Fuchs, D; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M; Austrian Breast and Colorectal Cancer Study Group Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Clin Cancer Res. 2017; 23(14):3676-3683 Doi: 10.1158/1078-0432.CCR-16-2373 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Tiran, V; Lindenmann, J; Brcic, L; Heitzer, E; Stanzer, S; Tabrizi-Wizsy, NG; Stacher, E; Stoeger, H; Popper, HH; Balic, M; Dandachi, N Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition.
Sci Rep. 2017; 7(1):10040-10040 Doi: 10.1038/s41598-017-09929-0 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Tiran, V; Stanzer, S; Heitzer, E; Meilinger, M; Rossmann, C; Lax, S; Tsybrovskyy, O; Dandachi, N; Balic, M Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.
PLoS One. 2017; 12(4):e0175223-e0175223 Doi: 10.1371/journal.pone.0175223 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Suppan, C; Balic, M Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016.
Memo. 2017; 10(2):82-85 Doi: 10.1007/s12254-017-0328-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Zeitschrift)

** Bjelic-Radisic, V; Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Greil, R; Wette, V; Petzer, A; Sevelda, P; Egle, D; Dubsky, P; Fitzal, F; Jakesz, R; Balic, M; Frantal, S; Solkner, L; Gnant, M Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax (R)) in the preoperative treatment of women with primary breast cancer (ABCSG-34)
ANN ONCOL. 2017; 28: -42nd European-Society-for-Medical-Oncology Congress (ESMO); SEP 08-12, 2017; Madrid, SPAIN. [Oral Communication]
Web of Science

 

** Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)
CANCER RES. 2017; 77: -San Antonio Breast Cancer Symposium; DEC 06-10, 2016; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS16-P5-15-13 [Poster]
Web of Science FullText FullText_MUG

 

** Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Greil, R; Rudas, M; Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Michael, G Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)
CANCER RES. 2017; 77: -San Antonio Breast Cancer Symposium; DEC 06-10, 2016; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS16-P6-10-01 [Poster]
Web of Science FullText FullText_MUG

 

** Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Gruber, C; Bartsch, R; Fridrik, M; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer
CANCER RES. 2017; 77: -San Antonio Breast Cancer Symposium; DEC 06-10, 2016; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS16-P1-09-10 [Poster]
Web of Science FullText FullText_MUG

 

** Suppan, C; Tiran, V; Heitzer, E; Auer, M; Cote, RJ; Datar, RH; Dandachi, N; Balic, M Serial blood draws in metastatic breast cancer patients undergoing systemic treatment analysed by size based CTC detection and mFAST Seq cell free DNA analysis
EUR J CANCER. 2017; 72: S39-S40. Doi: 10.1016/S0959-8049(17)30211-3 [Poster]
Web of Science FullText FullText_MUG

 

2016

Abstract (Zeitschrift)

** Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Artner-Matuschek, S; Fitzal, F; Marth, C; Sevelda, P; Mlineritsch, B; Steger, GG; Manfreda, D; Exner, R; Egle, D; Bergh, J; Kainberger, F; Talbot, S; Warner, D; Fesl, C; Singer, CF The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial
CANCER RES. 2016; 76: -38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; DEC 08-12, 2015; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS15-S2-02 [Keynote lecture]
Web of Science FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Fridrik, M; Petzer, A; Hubalek, M; Petru, E; Jager, T; Andel, J; Balic, M; Ulmer, H; Mlineritsch, B; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6)
CANCER RES. 2016; 76: -38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; DEC 08-12, 2015; San Antonio, TX. Doi: 10.1158/1538-7445.SABCS15-P1-13-10 [Poster]
Web of Science FullText FullText_MUG

 

** Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Mlineritsch, B; Greil, R Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK. Doi: 10.1093/annonc/mdw365.18 [Poster]
Web of Science FullText FullText_MUG

 

2015

Originalarbeit (Zeitschrift)

** Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Knauer, M; Moik, M; Jakesz, R; Seifert, M; Taucher, S; Bjelic-Radisic, V; Balic, M; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Selim, U; Fitzal, F; Hochreiner, G; Wette, V; Sevelda, P; Ploner, F; Bartsch, R; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Ann Oncol. 2015; 26(2):313-320 Doi: 10.1093/annonc/mdu544 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger, E; Bjelic-Radisic, V; Artner-Matuschek, S; Fitzal, F; Marth, C; Sevelda, P; Mlineritsch, B; Steger, GG; Manfreda, D; Exner, R; Egle, D; Bergh, J; Kainberger, F; Talbot, S; Warner, D; Fesl, C; Singer, CF; Austrian Breast and Colorectal Cancer Study Group Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
LANCET. 2015; 386(9992): 433-443. Doi: 10.1016/S0140-6736(15)60995-3
Web of Science PubMed FullText FullText_MUG

 

** Gnant, M; Sestak, I; Filipits, M; Dowsett, M; Balic, M; Lopez-Knowles, E; Greil, R; Dubsky, P; Stoeger, H; Rudas, M; Jakesz, R; Ferree, S; Cowens, JW; Nielsen, T; Schaper, C; Fesl, C; Cuzick, J Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Ann Oncol. 2015; 26(8):1685-1691 Doi: 10.1093/annonc/mdv215 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Suppan, C; Bjelic-Radisic, V; La Garde, M; Groselj-Strele, A; Eberhard, K; Samonigg, H; Loibner, H; Dandachi, N; Balic, M Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.
BMC Cancer. 2015; 15:1027-1027 Doi: 10.1186/s12885-015-2005-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Editorial

** Datar, RH; Balic, M; Cote, RJ Circulating Tumor Cells: Where From Here?
Semin Oncol. 2015; 42(4):515-517 Doi: 10.1053/j.seminoncol.2015.05.010
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Balic, M What is the role of resection of primary tumor in metastatic breast cancer? What is the role of cancer stem cells and circulating tumor cells and clinical state of the art
ONCOL RES TREAT. 2015; 38: 179-179.-Jahrestagung der DGHO, OeGHO, SGMO und SGH; 09.-13.10.2015; Basel. [Oral Communication]
Web of Science

 

** Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Radisic, VB; Bergh, JCS; Fitzal, F; Egle, D; Mlineritsch, B; Steger, GG; Talbot, S; Warner, DJ; Fesl, C; Singer, CF Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.
J CLIN ONCOL. 2015; 33(15):-Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO); MAY 29-JUN 02, 2015; Chicago, IL. Doi: 10.1200/jco.2015.33.15_suppl.504 [Oral Communication]
Web of Science FullText FullText_MUG

 

** Steger, GG; Greil, R; Hubalek, M; Fridrik, MA; Singer, CF; Bartsch, R; Balic, M; Dubsky, P; Egle, D; Gampenrieder, SP; Pfeiler, G; Mayr, D; Czech, T; Rinnerthaler, G; Exner, R; Petzer, AL; Sevelda, P; Lang, A; Rudas, M; Krause, B; Seifert, M; Frantal, S; Zielinski, CC; Gnant, M Bevacizumab in combination with docetaxel plus trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study
CANCER RES. 2015; 75(9):-37th Annual CTRC-AACR San Antonio Breast Cancer Symposium; DEC 09-13, 2014; San Antonio, TX.
Web of Science

 

2014

Originalarbeit (Zeitschrift)

** Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO; Austrian Breast and Colorectal Cancer Study Group Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Ann Oncol. 2014; 25(2):339-345 Doi: 10.1093/annonc/mdt494 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Heitzer, E; Artl, M; Filipits, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Höfler, G; Samonigg, H; Schaberl-Moser, R; Balic, M; Dandachi, N Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Mod Pathol. 2014; 27(6):906-915 Doi: 10.1038/modpathol.2013.204 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Suppan, C; Bjelic-Radisic, V; La Garde, M; Samonigg, H; Dandachi, N; Balic, M N/L Ratio does not have predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy
EUR J CANCER. 2014; 50: S193-S193.-9th European Breast Cancer Conference (EBCC); MAR 19-21, 2014; Glasgow, SCOTLAND. [Poster]
Web of Science

 

** Suppan, C; Milkovic, L; Gasparovic, AC; Samonigg, H; Dandachi, N; Balic, M Higher levels of HNE are associated with disease aggressiveness and worse outcome in breast cancer patients
EUR J CANCER. 2014; 50: S70-S70.-9th European Breast Cancer Conference (EBCC); MAR 19-21, 2014; Glasgow, SCOTLAND. [Poster]
Web of Science

 

2013

Originalarbeit (Zeitschrift)

** Balic, M; Schwarzenbacher, D; Stanzer, S; Heitzer, E; Auer, M; Geigl, JB; Cote, RJ; Datar, RH; Dandachi, N Genetic and epigenetic analysis of putative breast cancer stem cell models.
BMC Cancer. 2013; 13(7):358-358 Doi: 10.1186/1471-2407-13-358 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Balic, M; Williams, A; Lin, H; Datar, R; Cote, RJ Circulating Tumor Cells: From Bench to Bedside.
Annu Rev Med. 2013; 64(7):31-44 Doi: 10.1146/annurev-med-050311-163404 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gnant, M; Pfeiler, G; Stöger, H; Mlineritsch, B; Fitzal, F; Balic, M; Kwasny, W; Seifert, M; Stierer, M; Dubsky, P; Greil, R; Steger, G; Samonigg, H; Fesl, C; Jakesz, R The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Br J Cancer. 2013; 109(3):589-596 Doi: 10.1038/bjc.2013.367 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Hofmann, G; Balic, M; Dandachi, N; Resel, M; Schippinger, W; Regitnig, P; Samonigg, H; Bauernhofer, T The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.
Clin Biochem. 2013; 46(15):1585-1589 Doi: 10.1016/j.clinbiochem.2013.06.010
Web of Science PubMed FullText FullText_MUG

 

** Pfeiler, G; Stöger, H; Dubsky, P; Mlineritsch, B; Singer, C; Balic, M; Fitzal, F; Moik, M; Kwasny, W; Selim, U; Renner, K; Ploner, F; Steger, GG; Seifert, M; Hofbauer, F; Sandbichler, P; Samonigg, H; Jakesz, R; Greil, R; Fesl, C; Gnant, M; ABCSG Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Br J Cancer. 2013; 108(7):1408-1414 Doi: 10.1038/bjc.2013.114 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Schwarzenbacher, D; Balic, M; Pichler, M The role of microRNAs in breast cancer stem cells.
Int J Mol Sci. 2013; 14(7):14712-14723 Doi: 10.3390/ijms140714712 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Zeitschrift)

** Suppan, C; Bjelic-Radisic, V; La Guarde, M; Dandachi, N; Balic, M Neutrophil/Lymphocyte Ratio does not have predictive or prognostic value in breast cancer patients undergoing neoadjuvant systemic therapy
ONKOLOGIE. 2013; 36: 158-158. [Poster]
Web of Science

 

** Suppan, C; Milkovic, L; Gasparovic, AC; Waeg, G; Dandachi, N; Balic, M Higher levels of HNE are associated with disease aggressiveness and worse outcome of breast cancer patients
ONKOLOGIE. 2013; 36: 176-176.
Web of Science

 

2012

Originalarbeit (Zeitschrift)

** Balic, M; Lin, H; Williams, A; Datar, RH; Cote, RJ Progress in circulating tumor cell capture and analysis: implications for cancer management.
Expert Rev Mol Diagn. 2012; 12(3):303-312 Doi: 10.1586/erm.12.12 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Gnant, M; Balic, M; Petru, E; Raunik, W; Singer, CF; Steger, GG; Watzke, IM; Brodowicz, T Treatment of Bone Metastases in Patients with Advanced Breast Cancer.
Breast Care (Basel). 2012; 7(2):92-98 Doi: 10.1159/000338650 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Williams, A; Balic, M; Datar, R; Cote, R Size-based enrichment technologies for CTC detection and characterization.
Recent Results Cancer Res. 2012; 195: 87-95. Doi: 10.1007/978-3-642-28160-0_8
PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Heitzer, E; Marija, B; Resel, M; Graf, R; Weissenbacher, B; Schaberl-Moser, R; Dandachi, N; IDENTIFICATION OF PROGNOSTIC METHYLATION MARKERS IN PATIENTS WITH EARLY STAGE COLORECTAL CANCER.
ANN ONCOL. 2012; 23: 87-87.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN. [Poster]
Web of Science

 

** Rossmann, C; Balic, M; Krippl, P; COMPARISON OF OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER PATIENTS - DAILY PRACTICE VERSUS RANDOMIZED TRIALS.
ANN ONCOL. 2012; 23: 95-95.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN. [Poster]
Web of Science

 

2011

Originalarbeit (Zeitschrift)

** Balic, M; Rapp, N; Stanzer, S; Lin, H; Strutz, J; Szkandera, J; Daidone, MG; Samonigg, H; Cote, RJ; Dandachi, N Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells.
Appl Immunohistochem Mol Morphol. 2011; 19(1):33-40 Doi: 10.1097/PAI.0b013e3181ebf4e8
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Übersichtsarbeit

** Lin, H; Balic, M; Zheng, S; Datar, R; Cote, RJ Disseminated and circulating tumor cells: Role in effective cancer management.
Crit Rev Oncol Hematol. 2011; 77(1):1-11 Doi: 10.1016/j.critrevonc.2010.04.008
Web of Science PubMed FullText FullText_MUG

 

2010

Originalarbeit (Zeitschrift)

** Balic, M; Williams, A; Dandachi, N; Cote, RJ Micrometastasis: detection methods and clinical importance.
Cancer Biomark. 2010; 9(1-6):397-419 Doi: 10.3233/CBM-2011-0161
Web of Science PubMed FullText FullText_MUG

 

** Birkhahn, M; Mitra, AP; Williams, AJ; Lam, G; Ye, W; Datar, RH; Balic, M; Groshen, S; Steven, KE; Cote, RJ Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.
Eur Urol. 2010; 57(1):12-20 Doi: 10.1016/j.eururo.2009.09.013 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Cipak, A; Mrakovcic, L; Ciz, M; Lojek, A; Mihaylova, B; Goshev, I; Jaganjac, M; Cindric, M; Sitic, S; Margaritoni, M; Waeg, G; Balic, M; Zarkovic, N Growth suppression of human breast carcinoma stem cells by lipid peroxidation product 4-hydroxy-2-nonenal and hydroxyl radical-modified collagen.
Acta Biochim Pol. 2010; 57(2):165-171 Doi: 10.18388/abp.2010_2390 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Lin, HK; Zheng, S; Williams, AJ; Balic, M; Groshen, S; Scher, HI; Fleisher, M; Stadler, W; Datar, RH; Tai, YC; Cote, RJ Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells.
Clin Cancer Res. 2010; 16(20):5011-5018 Doi: 10.1158/1078-0432.CCR-10-1105 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Stanzer, S; Balic, M; Strutz, J; Heitzer, E; Obermair, F; Hauser-Kronberger, C; Samonigg, H; Dandachi, N Rapid and reliable detection of LINE-1 hypomethylation using high-resolution melting analysis.
Clin Biochem. 2010; 43(18):1443-1448 Doi: 10.1016/j.clinbiochem.2010.09.013
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Szkandera, J; Ploner, F; Bauernhofer, T; Kasparek, AK; Payer, F; Balic, M; Knechtel, G; Gerger, A; Gallè, G; Samonigg, H; Hofmann, G Paraneoplastic limbic encephalitis in a patient with extragonadal choriocarcinoma--significance of onconeural antibodies.
Onkologie. 2010; 33(8-9):452-454 Doi: 10.1159/000317269 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2009

Originalarbeit (Zeitschrift)

** Balic, M; Pichler, M; Strutz, J; Heitzer, E; Ausch, C; Samonigg, H; Cote, RJ; Dandachi, N High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis.
J Mol Diagn. 2009; 11(2):102-108 Doi: 10.2353/jmoldx.2009.080109 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

** Pichler, M; Balic, M; Stadelmeyer, E; Ausch, C; Wild, M; Guelly, C; Bauernhofer, T; Samonigg, H; Hoefler, G; Dandachi, N Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.
J Mol Diagn. 2009; 11(2):140-147 Doi: 10.2353/jmoldx.2009.080100 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Editorial

** Balic, M Disseminated tumor cells as biomarkers for breast cancer.
Biomark Med. 2009; 3(3):215-217 Doi: 10.2217/bmm.09.17 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2008

Originalarbeit (Zeitschrift)

** Stanzer, S; Dandachi, N; Balic, M; Resel, M; Samonigg, H; Bauernhofer, T Resistance to apoptosis and expansion of regulatory T cells in relation to the detection of circulating tumor cells in patients with metastatic epithelial cancer.
J Clin Immunol. 2008; 28(2):107-114 Doi: 10.1007/s10875-007-9139-2
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Stefatic, D; Riederer, M; Balic, M; Dandachi, N; Stanzer, S; Janesch, B; Resel, M; Ler, D; Samonigg, H; Bauernhofer, T Optimization of diagnostic ELISA-based tests for the detection of auto-antibodies against tumor antigens in human serum.
Bosn J Basic Med Sci. 2008; 8(3):245-250 Doi: 10.17305/bjbms.2008.2926 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Stanzer, S; Dandachi, N; Balic, M; Bauernhofer, T; Samonigg, H The role of NKG2D expression and soluble MICA and MICB in the higher onset of apoptosis of NK cell subsets in patients with epithelial cancer
WIEN KLIN WOCHENSCHR. 2008; 120(15-16):A46-A46. [Poster]
Web of Science

 

2007

Originalarbeit (Zeitschrift)

** Ausch, C; Dandachi, N; Buxhofer-Ausch, V; Balic, M; Huber, K; Bauernhofer, T; Ogris, E; Hinterberger, W; Braun, S; Schiessel, R Immunomagnetic CD45 depletion does not improve cytokeratin 20 RT-PCR in colorectal cancer.
Clin Chem Lab Med. 2007; 45(3):351-356 Doi: 10.1515/CCLM.2007.059
Web of Science PubMed FullText FullText_MUG

 

** Schippinger, W; Dandachi, N; Regitnig, P; Hofmann, G; Balic, M; Neumann, R; Samonigg, H; Bauernhofer, T The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
Am J Clin Pathol. 2007; 128(4):630-637 Doi: 10.1309/51KPD70348RP6XTE [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Zheng, S; Lin, H; Liu, JQ; Balic, M; Datar, R; Cote, RJ; Tai, YC Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells.
J Chromatogr A. 2007; 1162(2):154-161 Doi: 10.1016/j.chroma.2007.05.064
Web of Science PubMed FullText FullText_MUG

 

2006

Originalarbeit (Zeitschrift)

** Balic, M; Lin, H; Young, L; Hawes, D; Giuliano, A; McNamara, G; Datar, RH; Cote, RJ Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Clin Cancer Res. 2006; 12(19):5615-5621 Doi: 10.1158/1078-0432.CCR-06-0169 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Balic, M; Dandachi, N; Lin, H; Datar, RH Cancer metastasis: advances in the detection and characterization of disseminated tumour cells facilitate clinical translation.
Natl Med J India. 2006; 18(5):250-255
Web of Science PubMed

 

2005

Originalarbeit (Zeitschrift)

** Balic, M; Dandachi, N; Hofmann, G; Samonigg, H; Loibner, H; Obwaller, A; van der Kooi, A; Tibbe, AG; Doyle, GV; Terstappen, LW; Bauernhofer, T Comparison of two methods for enumerating circulating tumor cells in carcinoma patients.
Cytometry B Clin Cytom. 2005; 68(1):25-30 Doi: 10.1002/cyto.b.20065 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

** Bauernhofer, T; Zenahlik, S; Hofmann, G; Balic, M; Resel, M; Pirchmoser, R; Regitnig, P; Ambros, P; Dandachi, N; Samonigg, H Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer.
Oncol Rep. 2005; 13(2):179-184
Web of Science PubMed FullText Google Scholar

 

** Dandachi, N; Balic, M; Stanzer, S; Halm, M; Resel, M; Hinterleitner, TA; Samonigg, H; Bauernhofer, T Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients.
J Mol Diagn. 2005; 7(5):631-637 Doi: 10.1016/S1525-1578(10)60597-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Abstract (Zeitschrift)

** Hofmann, G; Dandachi, N; Balic, M; Schippinger, W; Wernecke, KD; Samonigg, H; Bauernhofer, T Quantitative measurement of soluble E-cadherin in sera of breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy and its predictive and prognostic value.
J CLIN ONCOL 2005 23: 70S-70S.
Web of Science

 

** Samonigg, H; Himmler, G; Gnant, M; Gastl, G; Loibner, H; Possinger, K; Bauernhofer, T; Dandachi, N; Balic, M; Steger, G; Obwaller, A A multicenter phase II, open-label trial of multiple doses of cancer vaccine candidate IGN101 to evaluate efficacy against disseminated tumor cells in blood.
J CLIN ONCOL 2005 23: 180S-180S.
Web of Science

 

2003

Abstract (Zeitschrift)

** Obwaller, A; Balic, M; van der Kooi, A; Dandachi, N; Himmler, G; Mudde, GC; Peball, B; Grunt, S; Oberkleiner, P; Doyle, GV; Terstappen, LWMM; Bauernhofer, T; Samonigg, H; Loibner, H Comparative analysis of three different methods for the detection of disseminated tumor cells
J IMMUNOTHER 2003 26: S49-S50.
Web of Science

 

** Samonigg, H; Hofmann, G; Bauernhofer, T; Balic, M; Stöger, H; Groiss, F; Himmler, G; Schuster, M; Rosenkaimer, F; Loibner, H Phase if trial to explore the influence of concomitant chemotherapies on the immunogenicity of the cancer vaccine IGN101 in patients with epithelial cancers
J IMMUNOTHER 2003 26: S14-S14.
Web of Science

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum